Plenary:

T. Facon, J. Mary, J. Harousseau, F. Huguet, C. Berthou, B. Grosbois, B. Anglaret, A. Azzedine, P. Rodon, A. Peny Intergroupe Francophone du Myélome

Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma
J Clin Oncol (Meeting Abstracts) 2006 24: 1. [Abstract]  

Plenary Presentation:

P. Paschka, G. Marcucci, A. S. Ruppert, K. Mrózek, H. Chen, R. A. Kittles, T. Vukosavljevic, D. Perrotti, R. A. Larson, and C. D. Bloomfield

Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study
J Clin Oncol (Meeting Abstracts) 2006 24: 2. [Abstract]  

Genitourinary Cancer:

R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. T. Kim, C. M. Baum, and R. A. Figlin

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: LBA3. [Abstract]  

G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, T. O’Toole, S. Kong, and L. Moore

A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: LBA4. [Abstract]  

M. I. Milowsky, M. Galsky, D. J. George, J. M. Lewin, C. P. Rozario, T. Marshall, M. Chang, D. M. Nanus, I. J. Webb, and H. I. Scher

Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4500. [Abstract]  

B. Escudier, C. Szczylik, T. Demkow, M. Staehler, F. Rolland, S. Negrier, T. E. Hutson, U. J. Scheuring, B. Schwartz, and R. M. Bukowski

Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4501. [Abstract]  

A. Ravaud, J. Gardner, R. Hawkins, H. Von der Maase, N. Zantl, P. Harper, F. Rolland, B. Audhuy, J. Machiels, I. El-Hariry Tykerb Renal Cell Cancer Study Group and GSK CoreT

Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4502. [Abstract]  

B. T. Teh, X. J. Yang, M. Tan, H. L. Kim, W. Stadler, N. G. Vogelzang, R. Amato, R. Figlin, A. Belldegrun, and C. G. Rogers

Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis
J Clin Oncol (Meeting Abstracts) 2006 24: 4503. [Abstract]  

M. J. Donovan, H. Scher, P. Scardino, A. Kotsianti, and C. Cordon-Cardo

Systems pathology for building predictive models: The androgen receptor as a prototype biomarker in prostate cancer progression and targeted therapeutic response assessment
J Clin Oncol (Meeting Abstracts) 2006 24: 4504. [Abstract]  

P. M. Venner, C. Ryan, D. P. Petrylak, G. S. Chatta, J. Ruether, K. N. Chi, J. Curd, and T. M. Beer

Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants
J Clin Oncol (Meeting Abstracts) 2006 24: 4505. [Abstract]  

W. L. Dahut, C. D. Scripture, E. M. Posadas, S. Wu, P. M. Arlen, J. L. Gulley, J. Wright, C. C. Chen, E. Jones, and W. D. Figg

Bony metastatic disease responses to sorafenib (BAY 43–9006) independent of PSA in patients with metastatic androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4506. [Abstract]  

R. C. Chen, J. A. Clark, S. P. Mitchell, and J. A. Talcott

Long-term outcomes after local treatments for prostate cancer by functional categories: Late changes, different results
J Clin Oncol (Meeting Abstracts) 2006 24: 4507. [Abstract]  

S. D. Fosså, J. Chen, G. M. Dores, K. A. McGlynn, S. J. Schonfeld, L. B. Travis NCI Testicular Cancer Research Group

Long-term non-cancer mortality among 39,657 one-year testicular cancer survivors (TCSs)
J Clin Oncol (Meeting Abstracts) 2006 24: 4508. [Abstract]  

D. Raghavan, M. S. Davis, D. Tsao-Wei, R. Ross, and S. Groshen

Increased late toxicity in 12–20 year survivors of germ cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4509. [Abstract]  

D. F. Bajorin, C. R. Nichols, K. A. Margolin, J. Bacik, P. G. Richardson, N. J. Vogelzang, L. Einhorn, M. Mazumdar, G. J. Bosl, and R. J. Motzer

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB
J Clin Oncol (Meeting Abstracts) 2006 24: 4510. [Abstract]  

A. Lorch, O. Rick, J. T. Hartmann, C. Kollmannsberger, B. Metzner, I. Schmidt-Wolf, W. E. Berdel, R. Schirren, J. Beyer, C. Bokemeyer for the German Testicular Cancer Study Group

Single versus sequential high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ-cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4511. [Abstract]  

P. Albers, R. Siener, S. Krege, H. Schmelz, K. Dieckmann, A. Heidenreich, P. Kwasny, M. Pechoel, J. Lehmann, R. Fimmers, and M. Hartmann

One course of adjuvant PEB chemotherapy versus retroperitoneal lymph node dissection in patients with stage I non-seminomatous germ-cell tumors (NSGCT): Results of the German Prospective Multicenter Trial (Association of Urological Oncology [AUO]/German Testicular Cancer Study Group [GTCSG] Trial 01–94)
J Clin Oncol (Meeting Abstracts) 2006 24: 4512. [Abstract]  

F. M. Calais Da Silva, F. Calais Da Silva, A. Bono, M. Brausi, P. Whelan, A. Queimadelos, J. Portillo, J. Portillo, Z. Kirkali, C. Robertson South European Uroncological Group

Phase III intermittent MAB vs continuous MAB
J Clin Oncol (Meeting Abstracts) 2006 24: 4513. [Abstract]  

A. J. Stephenson, A. Pollack, M. W. Kattan, P. T. Scardino Post-Prostatectomy Radiotherapy Consortium

Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4514. [Abstract]  

M. D. Michaelson, H. Lee, D. S. Kaufman, P. W. Kantoff, J. Finkelstein, and M. R. Smith

Annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized placebo-controlled trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4515. [Abstract]  

D. R. Berthold, G. Pond, R. De Wit, M. A. Eisenberger, and I. F. Tannock

Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study
J Clin Oncol (Meeting Abstracts) 2006 24: 4516. [Abstract]  

M. Hussain, C. M. Tangen, P. F. Schellhammer, E. D. Crawford, C. S. Higano, G. Wilding, A. Akdas, E. J. Small, B. Donnelly, and D. Raghavan

Absolute PSA value after androgen deprivation (AD) is a strong independent predictor of survival in new metastatic (D2) prostate cancer (PCa): Data from Southwest Oncology Group Trial 9346 (INT-0162)
J Clin Oncol (Meeting Abstracts) 2006 24: 4517. [Abstract]  

T. M. Beer, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. Chatta, J. Ruether, K. N. Chi, A. Arroyo, and F. W. Clow

Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT
J Clin Oncol (Meeting Abstracts) 2006 24: 4518. [Abstract]  

G. M. Mead, G. J. Rustin, S. P. Stenning, P. Vasey, N. Aass, R. Huddart, M. Sokal, and S. Kirk

Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis
J Clin Oncol (Meeting Abstracts) 2006 24: 4519. [Abstract]  

R. Huddart, M. O’Doherty, A. Padhani, G. Rustin, G. Mead, J. K. Joffe, P. Vasey, S. Hain, S. J. Kirk, S. P. Stenning National Cancer Research Institute Testis Cancer Clinical Studies Group

A prospective study of ¹⁸FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22
J Clin Oncol (Meeting Abstracts) 2006 24: 4520. [Abstract]  

M. De Wit, M. Hartmann, W. Brenner, L. Weißbach, H. Amthauer, C. Franzius, S. Kliesch, S. Krege, R. Heicappell, R. Bares, and C. Bokemeyer

[18F]-FDG-PET in germ cell tumors following chemotherapy: Results of the German multicenter trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4521. [Abstract]  

B. I. Rini, D. J. George, M. D. Michaelson, J. E. Rosenberg, R. M. Bukowski, J. A. Sosman, W. M. Stadler, K. Margolin, T. E. Hutson, and C. M. Baum

Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4522. [Abstract]  

R. M. Bukowski, F. Kabbinavar, R. A. Figlin, K. Flaherty, S. Srinivas, U. Vaishampayan, H. Drabkin, J. Dutcher, F. Scappaticci, and D. McDermott

Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4523. [Abstract]  

T. Eisen, R. M. Bukowski, M. Staehler, C. Szczylik, S. Oudard, W. M. Stadler, B. Schwartz, R. Simantov, M. Shan, B. Escudier for The Sorafenib TARGETs Clinical Trial Group

Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival
J Clin Oncol (Meeting Abstracts) 2006 24: 4524. [Abstract]  

C. W. Ryan, B. H. Goldman, P. N. Lara, Jr., T. M. Beer, H. A. Drabkin, and E. Crawford

Sorafenib plus interferon-2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412
J Clin Oncol (Meeting Abstracts) 2006 24: 4525. [Abstract]  

G. V. Kondagunta, J. Bacik, N. Ishill, V. Reuter, L. H. Schwartz, J. Korkola, J. Deluca, S. Sweeney, R. S. K. Chaganti, and R. J. Motzer

Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response
J Clin Oncol (Meeting Abstracts) 2006 24: 4528. [Abstract]  

P. H. De Mulder, J. Roigas, S. Gillessen, S. Srinivas, P. Pisa, N. Vogelzang, G. Fountzilas, C. Peschel, C. Baum, and B. Escudier

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4529. [Abstract]  

R. J. Amato, A. Misellati, M. Khan, and S. Chiang

A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4530. [Abstract]  

B. E. Houk, M. Amantea, R. J. Motzer, M. D. Michaelson, B. I. Rini, D. J. George, B. G. Redman, G. R. Hudes, B. Poland, and C. L. Bello

Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4531. [Abstract]  

M. Tan, B. Teh International Kidney Cancer Study Group

The von Hippel-Lindau gene mutation is associated with the good-prognosis profiling subtype of clear cell renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4532. [Abstract]  

L. Marsh, M. Khan, M. Needle, and R. Amato

Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4533. [Abstract]  

R. Dhanda, K. Gondek, J. Song, D. Cella, R. M. Bukowski, and B. Escudier

A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo
J Clin Oncol (Meeting Abstracts) 2006 24: 4534. [Abstract]  

R. A. Figlin, G. V. Kondagunta, S. Yazji, R. J. Motzer, and R. M. Bukowski

Phase II study of volociximab (M200), an 5ß1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4535. [Abstract]  

S. Negrier, D. Perol, A. Ravaud, J. O. Bay, S. Oudard, P. Fargeot, R. Delva, G. Deplanque, G. Gravis, B. Escudier for The French Immunotherapy Intergroup

Is intravenous (iv) IL2 superior to subcutaneous (sc) IL2 in good prognosis patients (pts) with metastatic renal cell carcinoma (MRCC) receiving a combination of IL2 and alpha interferon (IFN)? Results of the prospective randomized PERCY Duo trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4536. [Abstract]  

E. A. Ronnen, G. V. Kondagunta, C. Lau, P. Fischer, M. S. Ginsberg, M. Baum, S. T. Kim, I. Chen, C. M. Baum, and R. J. Motzer

A phase I study of sunitinib malate (SU11248) in combination with gefitinib in patients with metastatic renal cell carcinoma (mRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4537. [Abstract]  

J. Gollob, T. Richmond, J. Jones, W. K. Rathmell, G. Grigson, C. Watkins, B. Peterson, and J. Wright

Phase II trial of sorafenib plus interferon-alpha 2b (IFN-2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4538. [Abstract]  

T. K. Choueiri, R. Dreicer, B. I. Rini, P. Elson, J. Garcia, T. Mekhail, and R. M. Bukowski

Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4539. [Abstract]  

K. A. David, D. M. Nanus, M. I. Milowsky, J. Ritchey, A. Stewart, and P. R. Carroll

Perioperative chemotherapy treatment patterns in stage III transitional cell carcinoma (TCC) (1998–2003): A report from the National Cancer Data Base (NCDB)
J Clin Oncol (Meeting Abstracts) 2006 24: 4540. [Abstract]  

D. C. Smith, N. J. Mackler, M. H. Hussain, R. Dunn, J. E. Montie, D. Wood, C. T. Lee, D. Petrylak, D. Quinn, and U. Vaishampayan

Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report
J Clin Oncol (Meeting Abstracts) 2006 24: 4541. [Abstract]  

M. D. Galsky, A. Iasonos, S. Mironov, J. Scattergood, S. M. Donat, B. H. Bochner, H. W. Herr, P. Russo, M. G. Boyle, and D. F. Bajorin

Prospective trial of ifosfamide, paclitaxel, and cisplatin (ITP) in patients with advanced non-transitional cell (non-TCC) carcinomas of the urothelial tract
J Clin Oncol (Meeting Abstracts) 2006 24: 4542. [Abstract]  

R. Dreicer, S. Li, J. Manola, N. Haas, B. Roth, and G. Wilding

Phase II trial of epothilone B analogue BMS-247550 in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group
J Clin Oncol (Meeting Abstracts) 2006 24: 4543. [Abstract]  

P. Sharma, E. Sato, D. Bajorin, Y. Shen, S. Wen, V. Reuter, A. Jungbluth, S. Gnjatic, and L. Old

CD8⁺ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients
J Clin Oncol (Meeting Abstracts) 2006 24: 4544. [Abstract]  

M. S. Zaghloul, H. M. Khaled, M. Lotayef, and H. William

Adjuvant chemoradiotherapy after radical cystectomy in advanced high risk bladder cancer: A prospective randomized trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4545. [Abstract]  

J. M. Martin, T. Panzarella, D. R. Zwahlen, P. W. Chung, and P. Warde

Stage one seminoma: Evidence based guidelines for follow up
J Clin Oncol (Meeting Abstracts) 2006 24: 4546. [Abstract]  

M. Brydoy, J. Oldenburg, O. Klepp, R. M. Bremnes, E. Wist, O. Dahl, S. D. Fossa NUCG III Study group

Self-reported paresthesias, Raynaud’s phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TC) survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4547. [Abstract]  

P. J. Wiechno, M. A. Sadowska, K. S. Kubiak, T. Demkow, and J. Kaminska

Hormonal status and the quality of life of testicular cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4548. [Abstract]  

L. H. Einhorn, S. Williams, and R. Abonour

Salvage chemotherapy with high dose carboplatin + etoposide (HDCE) and peripheral blood stem cell transplant (PBSCT) in patients with germ cell tumors (GCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4549. [Abstract]  

D. S. Sharp, B. S. Carver, S. E. Eggener, G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld

Clinical outcome of patients managed for late relapse of germ cell tumor
J Clin Oncol (Meeting Abstracts) 2006 24: 4550. [Abstract]  

B. S. Carver, B. Shayegan, R. J. Motzer, D. Bajorin, G. V. Kondagunta, G. J. Bosl, and J. Sheinfeld

Predicting recurrence following post-chemotherapy retroperitoneal lymph node dissection for residual fibrosis or teratoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4551. [Abstract]  

J. Aparicio, J. Garcia-Puche, M. Lomas, F. Carabantes, S. Vazquez, C. Crespo, M. Climent, A. Murias, A. Oltra, E. Barrajon Spanish Germ Cell Cancer Group

Prognostic factors for relapse in stage I seminoma managed by surveillance or adjuvant carboplatin: A multivariate analysis on 588 cases
J Clin Oncol (Meeting Abstracts) 2006 24: 4552. [Abstract]  

M. R. Smith, F. Chu, J. Forrest, S. B. Malkowicz, D. Price, P. Sieber, K. G. Barnette, S. Segal, and M. S. Steiner

Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4553. [Abstract]  

J. R. Flanagan, C. Carney-Doebbeling, L. Jones, and C. Sweeney

Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4554. [Abstract]  

F. Saad, R. E. Coleman, R. Cook, M. R. Smith, J. E. Brown, J. Y. Hei, and Y. M. Chen

Predictors of clinical outcome in patients with bone metastases from prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4555. [Abstract]  

S. Halabi, S. Ou, N. J. Vogelzang, and E. J. Small

An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4556. [Abstract]  

G. R. Pond, D. R. Berthold, R. Dewit, M. Eisenberger, and I. F. Tannock

Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study
J Clin Oncol (Meeting Abstracts) 2006 24: 4557. [Abstract]  

A. M. Lin, J. E. Rosenberg, V. K. Weinberg, W. K. Kelly, M. D. Michaelson, M. Hussain, G. Wilding, M. E. Gross, and E. J. Small

Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP)
J Clin Oncol (Meeting Abstracts) 2006 24: 4558. [Abstract]  

M. Taplin, W. Xie, D. Morganstern, G. Bubley, M. Ernstoff, and M. Regan

Chemo-hormonal therapy for biochemical progression of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4559. [Abstract]  

M. Pomerantz, J. Manola, M. Taplin, G. Bubley, M. Inman, J. Lowell, P. Kantoff, and W. K. Oh

Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4560. [Abstract]  

K. Fizazi, G. R. Hudes, W. R. Berry, W. K. Kelly, J. C. Eymard, C. Logothetis, A. Le Maitre, J. P. Pignon, and S. Michiels

A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4561. [Abstract]  

P. Mathew, P. F. Thall, M. M. Johnson, W. K. Oh, A. A. Meluch, M. J. Morris, P. Troncoso, C. D. Bucana, I. J. Fidler, and C. J. Logothetis

Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)
J Clin Oncol (Meeting Abstracts) 2006 24: 4562. [Abstract]  

P. Sooriakumaran, P. Macanas-Pirard, S. Fox, H. Coley, G. Bucca, D. Lovell, A. Henderson, C. Smith, S. Langley, and R. Laing

A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4563. [Abstract]  

J. A. Garcia, C. Magi-Galluzzi, J. Rothaermel, P. Elson, M. Zhou, E. Klein, and R. Dreicer

Neoadjuvant GM-CSF and thalidomide in men with high-risk prostate carcinoma undergoing radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4564. [Abstract]  

F. Silva, F. M. Calais Da Silva, F. Gonçalves, T. Oliver South European Uroncological Group

Phase II screening study to assess the combination of a LHRH analogue, dexamethasone and a somatostatin analogue versus a LHRH analogue with dexamethasone in hormone refractory prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 4565. [Abstract]  

J. B. Nelson, D. J. Sleep, J. D. Isaacson, and M. A. Carducci

Limitation of prostate-specific antigen doubling time as a predictor of outcome in hormone-naive prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4566. [Abstract]  

A. V. D’Amico, J. Cullen, Y. Chen, and D. G. McLeod

Prostate-specific antigen velocity and the odds of detecting gleason 8 to 10 prostate cancer at biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 4567. [Abstract]  

S. J. Freedland, E. B. Humphreys, L. A. Mangold, M. Eisenberger, D. J. George, and A. W. Partin

Public health impact of PSA doubling time after radical prostatectomy on prostate cancer specific and overall survival
J Clin Oncol (Meeting Abstracts) 2006 24: 4568. [Abstract]  

F. J. Bianco, Jr., J. A. Eastham, A. J. Vickers, A. M. Serio, J. Pontes, E. A. Kline, and P. T. Scardino

Impact of the radical prostatectomy surgical technique and surgeon experience on freedom from cancer recurrence
J Clin Oncol (Meeting Abstracts) 2006 24: 4569. [Abstract]  

O. K. MacDonald, A. V. D’Amico, N. Sadetsky, D. C. Shrieve, A. W. Bakst, and P. R. Carroll

Predicting men at high risk for PSA failure after salvage radiotherapy for rising PSA following prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4570. [Abstract]  

D. V. Makarov, B. J. Trock, E. B. Humphreys, L. A. Mangold, M. A. Carducci, A. W. Partin, M. A. Eisenberger, and P. C. Walsh

Factors influencing prostate cancer specific mortality in patients receiving delayed androgen deprivation therapy for metastasis after biochemical recurrence following radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4571. [Abstract]  

H. K. Tsai, M. Chen, D. G. McLeod, P. R. Carroll, J. P. Richie, and A. V. D’Amico

Cancer-specific survival following radical prostatectomy or radiation therapy and short course hormonal therapy in men with localized, unfavorable-risk prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4572. [Abstract]  

J. Picus, S. Halabi, E. Small, A. Hussain, G. Philips, E. Kaplan, and N. Vogelzang

Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782
J Clin Oncol (Meeting Abstracts) 2006 24: 4573. [Abstract]  

Z. A. Dotan, K. Sathyamoorthy, F. J. Bianco, Jr, A. J. Stephenson, J. A. Eastham, P. Fearn, H. Schöder, H. I. Scher, P. T. Scardino, and M. W. Kattan

The probability of a positive bone scan in patients who were treated with adrogen ablasio therapy for rising PSA after radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4574. [Abstract]  

A. Berg, A. Berner, W. Lilleby, Ø. S. Bruland, S. D. Fosså, J. Nesland, and G. Kvalheim

Clinical impact of disseminated tumor cells in patients with non-metastatic prostate cancer treated by definitive radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4575. [Abstract]  

J. L. Wright, D. W. Lin, J. E. Cowan, J. Duchane, P. R. Carroll, M. S. Litwin the CaPSURE Investigators

Quality of life in young men after radical prostatectomy: Results from the CaPSURE registry
J Clin Oncol (Meeting Abstracts) 2006 24: 4576. [Abstract]  

B. Konety, J. Cowan, J. Duchane, P. Carroll CaPSURE Investigators

Patterns of primary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE
J Clin Oncol (Meeting Abstracts) 2006 24: 4577. [Abstract]  

G. Philips, B. Sanford, S. Halabi, D. Bajorin, and E. J. Small

Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102
J Clin Oncol (Meeting Abstracts) 2006 24: 4578. [Abstract]  

N. Shinohara, T. Harabayashi, S. Suzuki, K. Nagao, S. Nagamori, H. Matsuyama, K. Naito, and K. Nonomura

Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4579. [Abstract]  

D. Fitsialos, S. Seitz, E. Wiecek, M. Rasamoelisolo, J. Entwistle, M. Jewett, G. C. MacDonald, and N. Glover

Phase I/II study of vicinium given by intravesical administration in patients with superficial transitional cell carcinoma of the bladder: Phase I results
J Clin Oncol (Meeting Abstracts) 2006 24: 4580. [Abstract]  

Y. Mizutani, Y. N. Li, T. Shiraishi, T. Nakamura, T. Nomoto, K. Okihara, O. Ukimura, K. Yoneda, A. Kawauchi, and T. Miki

Prognostic significance of the level of serum osteoprotegerin in patients with bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4581. [Abstract]  

J. E. Rosenberg, S. Halabi, B. L. Sanford, A. L. Himelstein, J. N. Atkins, R. Hohl, S. L. Seagren, D. F. Bajorin, and E. J. Small

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4582. [Abstract]  

E. Herrmann, S. Bierer, M. Boegemann, E. Eltze, L. Hertle, and C. Wülfing

Expression of the endothelin axis and microvessel density in bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4583. [Abstract]  

C. Belda Iniesta, J. De Castro Carpeño, E. Casado Saenz, J. Feliu Batlle, F. Bernabeu, J. Alves, P. Cejas, M. Sereno, R. Perona, and M. Gonzalez Baron

Erythropoietin receptor expression in bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4584. [Abstract]  

C. Sammler, J. Beyer, C. Bokemeyer, J. Hartmann, W. Siegert, and O. Rick

Evaluation of prognosis in relapsed germ cell tumors: Identification of patients who profit from high dose chemotherapy (HDCT)
J Clin Oncol (Meeting Abstracts) 2006 24: 4585. [Abstract]  

A. H. Kortsaris, N. Diamantopoulos, G. Galaktidou, C. Andreadis, A. L. Boutis, C. Zavos, and D. Mouratidou

Relationship between insulin-like growth factor-1 and human testicular cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4586. [Abstract]  

T. Miki, Y. Mizutani, T. Nomoto, T. Nakamura, A. Kawauchi, D. Oka, K. Nishimura, N. Nonomura, and A. Okuyama

Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for cisplatin refractory germ cell tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 4587. [Abstract]  

D. A. Lewis, M. J. Brames, and L. H. Einhorn

Can patients (pts.) with refractory germ cell tumors (GCT) be cured after progression following high dose chemotherapy (HDCT) with tandem transplant? Results with paclitaxel + gemcitabine
J Clin Oncol (Meeting Abstracts) 2006 24: 4588. [Abstract]  

J. H. Oh, D. D. Baum, J. Ensor, S. Pham, M. D. Muddiman, S. Nguyen, and I. Chen

Long-term complications of platinum in testicular cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4589. [Abstract]  

S. J. Harland, G. Daugaard, A. Horwich, G. M. Mead, S. D. Fossa, M. Sokal, D. Morgenstern, R. Oliver, P. A. Cook, S. P. Stenning National Cancer Research Institute Testis Cancer Clinical Studies Group

The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2
J Clin Oncol (Meeting Abstracts) 2006 24: 4590. [Abstract]  

T. B. Dorff, R. Rupani, D. T. Wei, S. Groshen, J. Pinski, D. Raghavan, D. Quinn, and A. Aparicio

POMB-ACE therapy for patients with international germ cell cancer collaborative group (IGCCCG) poor risk germ cell tumors (GCT): The USC experience
J Clin Oncol (Meeting Abstracts) 2006 24: 4591. [Abstract]  

S. C. Palmer, J. Carver, L. Jacobs, K. H. Schmitz, C. Fung, E. Mohler, and D. J. Vaughn

Assessment of coronary heart disease risk in testicular cancer survivors
J Clin Oncol (Meeting Abstracts) 2006 24: 4592. [Abstract]  

P. E. Spiess, G. A. Brown, P. Liu, N. M. Tannir, S. Tu, A. M. Kamat, and L. L. Pisters

Predictors of survival in patients undergoing post-chemotherapy retroperitoneal lymph node dissection
J Clin Oncol (Meeting Abstracts) 2006 24: 4593. [Abstract]  

D. S. Thompson, F. A. Greco, D. R. Spigel, J. A. Sosman, E. Burkett, T. J. O’Rourke, L. Hart, and J. D. Hainsworth

Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4594. [Abstract]  

D. T. Eton, D. Cella, J. Bacik, and R. J. Motzer

A brief symptom index for renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4595. [Abstract]  

J. Patard, N. Rioux-Leclercq, K. Bensalah, and P. Fergelot

Biological significance of serum VEGF measurement in renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4596. [Abstract]  

I. Tamaskar, P. Shaheen, L. Wood, S. Hodnick, C. Nemec, J. Garcia, R. Dreicer, B. Rini, and R. Bukowski

Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents
J Clin Oncol (Meeting Abstracts) 2006 24: 4597. [Abstract]  

G. V. Raj, A. Iasonos, A. Bach, L. Hann, and P. Russo

Predicting the histology of renal masses using pre-operative Doppler ultrasonography
J Clin Oncol (Meeting Abstracts) 2006 24: 4598. [Abstract]  

S. Collins, P. M. Pierorazio, J. M. McKiernan, and M. C. Benson

Fractional percentage of tumor volume removed is a predictor of outcome following cytoreductive nephrectomy for metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4599. [Abstract]  

S. Srinivas, W. M. Stadler, R. Bukowski, R. Figlin, T. Hayes, E. W. Yankee, and E. Jonasch

Talactoferrin alfa may prolong progression-free survival in advanced renal carcinoma patients
J Clin Oncol (Meeting Abstracts) 2006 24: 4600. [Abstract]  

A. Al Hazzouri, S. A. Vaziri, M. Lynch, B. Schwartz, B. I. Rini, R. Bukowski, and R. Ganapathy

Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel Lindau protein (pVHL) expression and hypoxia
J Clin Oncol (Meeting Abstracts) 2006 24: 4601. [Abstract]  

P. Fergelot, N. Rioux-Leclercq, S. Zerrouki, K. Bensalah, and J. Patard

Relationship between VHL mutation status, tumor VEGF expression and plasma VEGF measurement in sporadic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4602. [Abstract]  

A. G. García, Sr., E. Esteban, C. G. Girón, P. Maroto, R. Andrés, A. Canelas, J. Caballido, J. Carles, E. Espinosa, and A. J. Lacave

Observational study in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 (rIL-2)
J Clin Oncol (Meeting Abstracts) 2006 24: 4603. [Abstract]  

X. Gao, P. Reddy, R. Dhanda, K. Gondek, Y. C. Yeh, W. M. Stadler, and E. Jonasch

Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4604. [Abstract]  

P. E. Shaheen, I. R. Tamaskar, R. N. Salas, B. I. Rini, J. Garcia, L. Wood, R. Dreicer, and R. M. Bukowski

Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib
J Clin Oncol (Meeting Abstracts) 2006 24: 4605. [Abstract]  

G. Hennig, H. Paus, D. Atkins, and S. Störkel

Comparative expression profiling with kinetic RT-PCR in paired fresh frozen and archived formalin-fixed, paraffin-embedded renal cell cancer and normal tissue
J Clin Oncol (Meeting Abstracts) 2006 24: 4606. [Abstract]  

S. M. Di Stasi, A. Giannantoni, M. Valenti, L. Storti, F. Attisani, T. Palloni, E. A. Jannini, M. Bibas, and G. Zampa

Multicenter, randomized, phase III trial comparing radical retropubic prostatectomy with conventional external beam radiotherapy for localized prostate cancer: An interim report
J Clin Oncol (Meeting Abstracts) 2006 24: 4607. [Abstract]  

A. Laplanche, P. Beuzeboc, J. Lumbroso, M. Di Palma, C. Theodore, D. Prapotnich, B. Escudier, J. Bouzy, V. Haddad, and K. Fizazi

A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine
J Clin Oncol (Meeting Abstracts) 2006 24: 4608. [Abstract]  

E. Small, C. Higano, N. Tchekmedyian, O. Sartor, B. Stein, R. Young, J. Vestal, W. Moseley, S. Fischkoff, and I. Lowy

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4609. [Abstract]  

J. Graff, M. Mori, H. Li, M. Garzotto, D. Penson, A. Potosky, and T. M. Beer

Predictors of overall and cancer-specific survival in patients with clinically localized prostate cancer (PC) treated with primary androgen deprivation therapy (PADT): Results from the Prostate Cancer Outcomes Study
J Clin Oncol (Meeting Abstracts) 2006 24: 4610. [Abstract]  

D. Douglas, H. Zhong, J. Ro, C. Oddoux, M. Pincus, J. Satagopan, W. Gerald, H. Scher, P. Lee, and I. Osman

Novel mutations in tyrosine kinase domain of epidermal growth factor receptor in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4611. [Abstract]  

P. M. Pierorazio, S. M. Lambert, T. R. McCann, A. E. Katz, C. A. Olsson, M. C. Benson, and J. M. McKiernan

Evaluating high-grade prostatic intraepithelial neoplasia as a predictor of outcome following radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 4612. [Abstract]  

M. J. Morris, M. I. Milowsky, N. Pandit-Taskar, C. Divgi, K. A. David, C. P. Rozario, S. Vallabhajosula, S. J. Goldsmith, H. I. Scher, and D. M. Nanus

Phase 2 trial of ¹⁷⁷Lutetium (¹⁷⁷Lu) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4613. [Abstract]  

J. S. Chan, C. W. Ryan, P. M. Venner, D. P. Petrylak, G. S. Chatta, J. Ruether, K. N. Chi, J. Young, C. Shen, and T. M. Beer

Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT
J Clin Oncol (Meeting Abstracts) 2006 24: 4614. [Abstract]  

S. Gogov, F. Hussain, G. Naglie, I. Tannock, N. E. Fleshner, M. D. Krahn, S. Duff Canning, P. Warde, and S. M. Alibhai

Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer?
J Clin Oncol (Meeting Abstracts) 2006 24: 4615. [Abstract]  

T. J. Daskivich, M. M. Regan, P. W. Kantoff, and W. K. Oh

Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4616. [Abstract]  

M. Garzotto, S. Mongoue-Tchokote, J. Shannon, L. Peters, M. H. Sokoloff, T. M. Beer, and M. Mori

Effect of obesity on PSA density (PSAD): A new clinical predictor of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4617. [Abstract]  

G. Liu, W. Wang, R. Dipaola, M. Carducci, and G. Wilding

A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: A trial of the Eastern Cooperative Oncology Group (E3803)
J Clin Oncol (Meeting Abstracts) 2006 24: 4618. [Abstract]  

A. Hung, L. P. Depaula, S. Mongoue-Tchokote, and M. Garzotto

Pre-treatment PSA velocity (PSAV) is not predictive of outcomes after radical prostatectomy (RP) in a referral cohort
J Clin Oncol (Meeting Abstracts) 2006 24: 4619. [Abstract]  

O. Sartor, C. L. Bennett, S. Halabi, M. Kattan, and P. Scardino

Race/ethnicity, literacy, and prostate cancer: Initial findings from the COMPARE registry
J Clin Oncol (Meeting Abstracts) 2006 24: 4620. [Abstract]  

S. Wu, E. Jones, J. Gulley, P. Arlen, C. Chen, W. Figg, and W. Dahut

Routine interval computed tomography in detecting new soft tissue disease in patients with androgen-independent prostate cancer (AIPC) and only bone metastasis
J Clin Oncol (Meeting Abstracts) 2006 24: 4621. [Abstract]  

P. A. Johnstone, M. Goodman, K. Ward, V. Assikis, and K. Ogan

Salvage prostatectomy for prostate cancer (CaP): Data from the Surveillance Epidemiology and End Results (SEER) database
J Clin Oncol (Meeting Abstracts) 2006 24: 4622. [Abstract]  

D. Crawford, N. Serkova, E. Gamito, R. Jones, C. O’Donnell, and T. Hedlund

Nuclear magnetic resonance spectroscopy of expressed prostatic secretions: Metabolite citrate and derivatives are potential markers of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4623. [Abstract]  

W. A. See, D. G. McLeod, P. Iversen, M. P. Wirth, J. Armstrong, S. Navani on behalf of the CASODEX Early Prostate Cancer Trialists’ Group

Effect of bicalutamide 150 mg on PSA progression in M0 prostate cancer: Results from the Early Prostate Cancer program
J Clin Oncol (Meeting Abstracts) 2006 24: 4624. [Abstract]  

O. Caffo, T. Sava, E. Comploj, A. Fariello, F. Zustovich, F. Valduga, M. Frisinghelli, R. Segati, C. Sacco, A. Perin, and G. Pappagallo

A multicentric phase II randomized trial of docetaxel (D) plus estramustine (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4625. [Abstract]  

C. J. Ryan, J. Rosenberg, A. Lin, L. Ruttner, V. Weinberg, and E. Small

Outcome of patients with non-metastatic versus metastatic hormone refractory prostate cancer (HRPC) treated with second-line hormonal therapy consisting of ketoconazole (keto) plus granulocyte macrophage colony stimulating factor (GM-CSF)
J Clin Oncol (Meeting Abstracts) 2006 24: 4626. [Abstract]  

B. Montgomery, D. Lin, C. Ryan, M. Garzotto, and T. M. Beer

Diethylstilbestrol and docetaxel: A phase II study in patients with metastatic, androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4627. [Abstract]  

P. Iversen, M. P. Wirth, W. A. See, II, D. G. McLeod, T. Morris, J. Armstrong on behalf of the CASODEX Early Prostate Cancer Trialists’ Group

The influence of nodal status on progression outcomes in patients with prostate cancer: Data from the Early Prostate Cancer program at 7.4 years
J Clin Oncol (Meeting Abstracts) 2006 24: 4628. [Abstract]  

M. P. Wirth, W. A. See, II, D. G. McLeod, P. Iversen, T. Morris, J. Armstrong on behalf of the CASODEX Early Prostate Cancer Trialists’ Group

Delaying metastatic disease progression in locally advanced disease – Results from the Early Prostate Cancer program at a median follow-up of 7.4 years
J Clin Oncol (Meeting Abstracts) 2006 24: 4629. [Abstract]  

D. J. Sleep, J. B. Nelson, D. P. Petrylak, J. D. Isaacson, and M. A. Carducci

Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone
J Clin Oncol (Meeting Abstracts) 2006 24: 4630. [Abstract]  

M. R. McKenzie, K. N. Chi, A. Neville, S. Ellard, B. Baerg, D. Ruether, E. Winquist, R. Segal, and H. Lukka

Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP)
J Clin Oncol (Meeting Abstracts) 2006 24: 4631. [Abstract]  

J. Domingo-Domenech, E. Gallardo, X. Filella, E. Fernandez, P. Fernandez, P. Gascon, and B. Mellado

Serum c-erbB-2 ectodomain (ECD) correlates with immunohistochemical c-erbB-2 expression and predicts an aggressive clinical outcome in hormone-independent prostate cancer (HIPC) patients (pts) treated with docetaxel (D)
J Clin Oncol (Meeting Abstracts) 2006 24: 4632. [Abstract]  

C. A. O’Brien, S. Mongoue-Tchokote, L. Collins, S. Spurgeon, L. Peters, T. M. Beer, M. Mori, and M. Garzotto

Assessment of PSA and digital rectal examination (DRE) for the detection of Gleason 7 prostate cancer in a referral population
J Clin Oncol (Meeting Abstracts) 2006 24: 4633. [Abstract]  

S. Marur, L. Heilbrun, O. Kucuk, M. L. Cher, J. Forman, E. Heath, and U. Vaishampayan

Phase II trial of weekly docetaxel and oral capecitabine in metastatic hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4634. [Abstract]  

L. K. Aguilar, B. Teh, W. Mai, J. Caillouet, G. Ayala, E. Aguilar-Cordova, and E. Butler

Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4635. [Abstract]  

A. Andea, I. Osman, P. Scardino, H. Scher, and W. Gerald

Mutational profiling of protein kinases in prostate carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 4636. [Abstract]  

R. K. Nam, K. W. Marshall, R. Zheng, H. W. Zhang, S. A. Narod, and C. C. Liew

Blood-based biomarkers for detecting aggressive prostate cancer at time of biopsy
J Clin Oncol (Meeting Abstracts) 2006 24: 4637. [Abstract]  

L. Abetz, V. Barghout, R. Arbuckle, V. Bosch, N. Shirina, and F. Saad

Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial
J Clin Oncol (Meeting Abstracts) 2006 24: 4638. [Abstract]  

A. Banu, D. Helley, E. Banu, A. M. Fischer, F. Scotte, A. Bouziane, and S. Oudard

Platelet microparticles (PMP): A predictive factor of overall survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4639. [Abstract]  

M. M. Regan, T. J. Daskivich, P. W. Kantoff, and W. K. Oh

Utility of prostate specific antigen doubling time (PSA-DT) at the start of androgen independent prostate cancer (AIPC) and immediately before chemotherapy in predicting efficacy of taxane chemotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4640. [Abstract]  

O. Stoss, P. Albers, M. Werther, D. Zielinsky, N. Jost, J. Rueschoff, and T. Henkel

Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4641. [Abstract]  

P. Carlini, E. Bria, M. Ciccarese, M. Milella, G. Arcangeli, M. Gallucci, E. Ruggeri, E. Terzoli, F. Cognetti, and D. Giannarelli

Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analsys of 6 randomized trials
J Clin Oncol (Meeting Abstracts) 2006 24: 4642. [Abstract]  

S. Kumar, C. Harrison, M. Shelley, and M. Mason

Meta-analysis of neo-adjuvant androgen deprivation therapy (AD) in localised prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4643. [Abstract]  

N. M. Hahn, C. Whalen, and C. J. Sweeney

Second-line pemetrexed (P) for the treatment of hormone refractory prostate cancer (HRPC): A Hoosier Oncology Group phase II study—Preliminary analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 4644. [Abstract]  

R. D. Nurani, K. E. Wallner, G. S. Merrick, P. Orio, J. Virgin, and L. True

The prognostic value of percent positive biopsies in intermediate to high risk prostate cancer treated with brachytherapy and supplemental beam radiotherapy
J Clin Oncol (Meeting Abstracts) 2006 24: 4645. [Abstract]  

M. Nakabayashi, W. Xie, M. M. Regan, D. M. Jackman, P. W. Kantoff, and W. K. Oh

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4646. [Abstract]  

P. U. Moffett, M. A. Choudry, L. A. Ferguson, D. A. Williams, R. V. La Rocca, F. J. Hendler, and D. A. Laber

Update on a phase II study of cyclophosphamide, etoposide and estramustine in patients with androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4647. [Abstract]  

T. Kang, P. Nichols, E. Skinner, S. Groshen, G. Valin, W. Ye, and D. Raghavan

Functional heterogeneity of prostatic intra-epithelial neoplasia: Length of hormonal therapy influences response
J Clin Oncol (Meeting Abstracts) 2006 24: 4648. [Abstract]  

M. Saraiya, D. Werny, and T. Thompson

Relationship of body mass index and other anthropometric measures and prostate specific antigen, NHANES 2001–2002
J Clin Oncol (Meeting Abstracts) 2006 24: 4649. [Abstract]  

S. F. Slovin, L. Daigneault, H. Dulude, C. Panchal, J. Richardson, T. Curley, A. Delacruz, M. Fleisher, M. Morris, and H. Scher

Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC)—The US experience
J Clin Oncol (Meeting Abstracts) 2006 24: 4650. [Abstract]  

J. E. Michels, S. Ellard, L. Le, N. Murray, E. Guns, A. Hagey, and K. N. Chi

A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 4651. [Abstract]  

N. J. Fitzsimons, S. Freedland, J. Presti, Jr., C. Amling, C. Kane, M. Terris, and W. Aronson

Is biopsy Gleason sum an independent predictor of biochemical progression following radical prostatectomy after adjusting for the pathological Gleason sum?
J Clin Oncol (Meeting Abstracts) 2006 24: 4652. [Abstract]  

T. Nelius, T. Klatte, F. Reiher, S. Filleur, R. Yap, and E. P. Allhoff

Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 4653. [Abstract]  

K. Touijer, F. Rabbani, J. Romero Otero, F. Secin, and B. Guillonneau

Extended vs. limited laparoscopic pelvic lymph node dissection for prostate cancer: The value of Partin tables in selection of the need for and the extent of dissection
J Clin Oncol (Meeting Abstracts) 2006 24: 4654. [Abstract]  

J. Bahary, K. Bae, D. Taussky, M. Roach, III, H. M. Sandler, and W. U. Shipley

Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of Radiation Therapy Oncology Group protocol 9413
J Clin Oncol (Meeting Abstracts) 2006 24: 4655. [Abstract]  

C. R. Porter, J. Wright, L. Borden, K. Jason, and K. Latchemsetty

Are men with larger prostates and bothersome voiding symptoms less likely to have significant prostate cancer?
J Clin Oncol (Meeting Abstracts) 2006 24: 4656. [Abstract]  

A. C. Ferrari, L. Wang, X. Liu, and X. Liu

Androgen receptor (AR) modulation strategies for recurrent prostate cancer (PC) without androgen suppression
J Clin Oncol (Meeting Abstracts) 2006 24: 4657. [Abstract]  

A. Reichle, J. Grassinger, K. Bross, J. Wilke, T. Suedhoff, A. Berand, W. Wieland, and R. Andreesen

Effect of anti-inflammatory therapy in patients with metastatic renal cell carcinoma on clinical response
J Clin Oncol (Meeting Abstracts) 2006 24: 14500. [Abstract]  

S. Thakkar, T. Hutson, J. Garcia, J. Rothaermal, M. Bart, and R. Dreicer

A phase II trial of gemcitabine and docetaxel in hormone-refractory metastatic prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14501. [Abstract]  

S. A. North, S. Marwaha, and P. M. Venner

The importance of etoposide dose intensity in the management of metastatic germ cell tumours and the role of paclitaxel in salvage treatment of relapsing patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14502. [Abstract]  

A. J. Montero, C. Diaz-Montero, X. Wang, B. W. McIntyre, and N. Tannir

Predictive utility of serum cytokine levels in patients with metastatic renal cell carcinoma (MRCC) treated with interferon alfa (IFNa)
J Clin Oncol (Meeting Abstracts) 2006 24: 14503. [Abstract]  

C. N. Moore, P. Creel, W. P. Petros, T. Torain, S. Yenser, J. Gockerman, H. Hurwitz, A. Garcia Turner, D. J. Sleep, and D. J. George

Phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14504. [Abstract]  

M. A. Moyad and T. A. Kirk

National study of patients, caregivers and physicians reveals pain associated with advanced prostate cancer as the primary concern
J Clin Oncol (Meeting Abstracts) 2006 24: 14505. [Abstract]  

J. Y. Luh, S. J. Wang, C. D. Fuller, and C. R. Thomas, Jr

A SEER database analysis of conditional survival for prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14506. [Abstract]  

O. Yossepowitch, S. E. Eggener, B. H. Bochner, S. M. Donat, H. W. Herr, and G. Dalbagni

Safety and efficacy of intravesical bacillus Calmette-Guérin instillations in steroid-treated and immunocompromised patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14507. [Abstract]  

J. H. Hayes, W. K. Oh, P. W. Kantoff, J. B. Manola, M. R. Smith, E. P. Gelmann, G. Bubley, S. P. Balk, and M. Taplin

Mifepristone (RU-486) in androgen independent prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14508. [Abstract]  

M. Zhou, I. Tamaskar, L. Sercia, B. I. Rini, and R. M. Bukowski

Expression of caveolin-1 in renal neoplasms
J Clin Oncol (Meeting Abstracts) 2006 24: 14509. [Abstract]  

I. Cordia, C. H. Ohlmann, U. Engelmann, and A. Heidenreich

Prognostic risk factors for survival following adjuvant chemotherapy for locally advanced urothelial bladder cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14510. [Abstract]  

J. Pettus, D. Sharp, Y. Ofer, A. Bach, and P. Russo

Tumor location does not impact return of renal function following partial nephrectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 14511. [Abstract]  

D. P. Petrylak, S. G. Mohile, G. Shelton, R. A. Carr, J. Steinberg, D. Sleep, J. Melia, M. J. Rieser, D. Nanus, and M. I. Milowsky

Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14512. [Abstract]  

L. Hart, T. Ciuleanu, J. Hainsworth, S. Oudard, E. R. Berger, J. Alexandre, K. N. Chi, D. Ruether, J. R. MacDonald, and E. Cvitkovic

Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 14513. [Abstract]  

H. Muniswamy, J. P. Dutcher, P. Mannam, S. Malik, V. Rusciano, L. Paul, and P. H. Wiernik

Role of prognostic factors in patients with metastatic renal cell carcinoma (MRCC) eligible for treatment with interleukin (IL2)
J Clin Oncol (Meeting Abstracts) 2006 24: 14514. [Abstract]  

B. Mellado, A. Font, L. A. Aparicio, E. Gallardo, J. R. Mel, A. Alcaraz, J. Areal, F. J. Gómez Veiga, N. Hannaoui, and P. Gascón

Phase II trial of weekly docetaxel (D) and complete androgen blockade (CAB) prior to radical prostatectomy (RP) in high-risk localized prostate cancer (PC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2006 24: 14515. [Abstract]  

M. Gittelman, P. Pommerville, J. De La Rosette, B. E. Persson, J. K. Jensen, T. K. Olesen on behalf of the Degarelix Study Groups

Degarelix: A gonadotropin-releasing hormone receptor (GnRH) blocker, tested in two one-year multicenter, randomized, dose-finding studies in prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14516. [Abstract]  

A. Misellati, S. Phan, and R. J. Amato

Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14518. [Abstract]  

B. Kasimis, V. Chang, J. Cogswell, N. Sambamoorthi, M. Gonzalez, S. Srinivas, F. Zhong, E. Morales, L. Duque, and M. Blumenfrucht

Combination therapy with docetaxel (D) and celecoxib (C) in patients (pts) with hormone resistant prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14519. [Abstract]  

D. R. Shaffer, L. E. Abrey, K. Beekman, C. Eicher, M. Morris, S. Slovin, J. Feldstein, S. Larson, N. Rosen, and H. I. Scher

A phase I/II trial of RAD 001 with gefitinib in patients with castrate metastatic prostate cancer and glioblastoma multiforme
J Clin Oncol (Meeting Abstracts) 2006 24: 14520. [Abstract]  

G. A. Gignac, M. J. Morris, L. H. Schwartz, E. Lis, and H. I. Scher

Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14521. [Abstract]  

C. Priolo, D. Tang, M. Brahmandam, B. Benassi, E. Sicinska, S. Ogino, A. Farsetti, A. Porrello, P. G. Febbo, J. Zimmermann, and M. F. Loda

USP2a is an oncogenic isopeptidase and a potential target in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14522. [Abstract]  

D. Sahi, C. H. Ohlmann, I. Cordia, U. Engelmann, and A. Heidenreich

PSA flare-up in patients with hormone-refractory prostate cancer (HRPCA) receiving docetaxel-based chemotherapy: Incidence and differentiation from progressive disease
J Clin Oncol (Meeting Abstracts) 2006 24: 14523. [Abstract]  

V. Tagalakis, H. Tamim, J. Collet, S. R. Kahn, M. Blostein, and J. A. Hanley

The effect of warfarin on the risk of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14524. [Abstract]  

T. Klatte, A. Ittenson, F. Röhl, M. Ecke, E. P. Allhoff, and M. Böhm

Perioperative immunomodulation with interferon-alpha in patients with renal cell carcinoma: Early results of a controlled phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 14525. [Abstract]  

P. Jiang and C. S. Higano

Phase I study of interleukin 2 (IL2) maintenance after induction with weekly docetaxel and estramustine in patients with metastatic hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14526. [Abstract]  

M. Kohli, J. Huang, G. Palapattu, R. Dennis, J. Yao, T. Lester, and W. Ricke

Cellular localization of thrombin in prostate: Implications for thrombin targeted therapy in prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14527. [Abstract]  

A. Mehta, M. Stein, S. Goodin, S. Yao, J. Shih, M. Todd, and R. S. Dipaola

Pre-treatment PSA doubling time (PSADT) predicts biochemical response to chemotherapy in patients with androgen sensitive PSA progression after local therapy
J Clin Oncol (Meeting Abstracts) 2006 24: 14528. [Abstract]  

S. Vázquez Estévez, J. Mel Lorenzo, E. Álvarez Gómez, and G. Quintero Aldana

A phase II study of biweekly docetaxel and vinorelbine for hormone-refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14529. [Abstract]  

F. Honecker, S. Glaesener, T. Rohlfing, T. H. Brummendorf, C. Bokemeyer, and S. Balabanov

Comparative proteome analysis of gonadal and extragonadal germ cell tumors
J Clin Oncol (Meeting Abstracts) 2006 24: 14530. [Abstract]  

M. C. Scholz, R. Lam, B. Guess, S. Strum, H. Johnson, and R. Jenrrich

Ultrasensitive PSA nadir on testosterone inactivating pharmaceuticals accurately predicts early prostate cancer progression
J Clin Oncol (Meeting Abstracts) 2006 24: 14531. [Abstract]  

J. S. Lam, R. H. Goel, A. J. Pantuck, R. A. Figlin, and A. S. Belldegrun

Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14532. [Abstract]  

W. K. Oh, J. Manola, R. W. Ross, A. Berkowitz, C. W. Ryan, K. M. Eilers, and T. M. Beer

A phase II trial of docetaxel plus carboplatin in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel chemotherapy: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 14533. [Abstract]  

P. Sperone, M. Volante, A. Berruti, E. Bollito, E. Frangipane, F. Daffara, M. Terzolo, G. Gorzegno, L. Dogliotti, and M. Papotti

Matrix metalloproteinase type 2 (MMP2) is selective expressed in adrenocortical carcinoma but not in adrenal adenoma: An immunohistochemical study
J Clin Oncol (Meeting Abstracts) 2006 24: 14534. [Abstract]  

W. Kassouf, R. Sanchez-Ortiz, P. Tamboli, S. Matin, and D. Swanson

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the presence of nonconventional histology
J Clin Oncol (Meeting Abstracts) 2006 24: 14535. [Abstract]  

R. Shazer, A. Bharne, E. Nepomuceno, J. Mirocha, C. Ramirez, D. Luthringer, S. Holden, D. B. Agus, and M. Gross

Biomarkers and obesity in surgically treated patients with prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14536. [Abstract]  

A. J. Rodney, A. Siefker-Radtke, N. M. Tannir, S. Swisher, G. Walsh, R. E. Millikan, and L. C. Pagliaro

Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M. D. Anderson Cancer Center (MDACC) experience
J Clin Oncol (Meeting Abstracts) 2006 24: 14538. [Abstract]  

A. J. Pantuck, P. Fergelot, J. Patard, J. Lam, A. S. Belldegrun, and R. A. Figlin

Pilot study of VHL mutation analysis to predict response to interleukin-2 in patients with metastatic renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14539. [Abstract]  

D. Huang, G. P. Casale, N. K. Wehbi, J. Tian, and G. P. Hemstreet, III

Altered expression of ß-catenin and UDP-glucose dehydrogenase in normal appearing acini of cancer-bearing prostate glands, detected by quantitative fluorescence imaging analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 14540. [Abstract]  

M. S. Wolf, J. A. Zagory, C. Chang, S. Knight, P. Ray, M. Kozloff, A. Starr, E. A. Lyons, S. Costello, and C. L. Bennett

Literacy and race predictors in localized prostate cancer treatment choice
J Clin Oncol (Meeting Abstracts) 2006 24: 14541. [Abstract]  

C. P. Evans, P. N. Lara, Jr, H. Kung, and J. C. Yang

Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): Pre-clinical rationale for a phase II trial
J Clin Oncol (Meeting Abstracts) 2006 24: 14542. [Abstract]  

G. V. Masucci, E. Andersson, L. Egevad, K. Kälkner, U. Harmenberg, M. Ryberg, S. Nilsson, and P. Pisa

High frequency of human leucocyte antigen (HLA) A2 and HLA-B7, -B44, -B15 and -DRB1–4 haplotypes in Swedish prostate cancer patients
J Clin Oncol (Meeting Abstracts) 2006 24: 14543. [Abstract]  

V. Barghout, L. Abetz, R. Arbuckle, V. Bosch, Y. Hei, and F. Saad

Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status
J Clin Oncol (Meeting Abstracts) 2006 24: 14544. [Abstract]  

G. Sonpavde, K. Slawin, J. M. Levitt, and L. Guariguata

Clinical experience with extended lymph node dissection during radical prostatectomy
J Clin Oncol (Meeting Abstracts) 2006 24: 14545. [Abstract]  

A. B. Jani, A. Shoushtari, and J. Feinstein

The role of androgen ablation with low dose rate brachytherapy in the treatment of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14546. [Abstract]  

L. A. Korde, A. Premkumar, J. L. Kramer, W. Linehan, S. Pfeiffer, G. Bratslavsky, and M. H. Greene

Testicular ultrasound (TU) screening in men from familial testicular cancer (FTC) kindreds
J Clin Oncol (Meeting Abstracts) 2006 24: 14547. [Abstract]  

K. Lang, N. Danchenko, K. Gondek, B. Schwartz, and D. Thompson

Burden of illness analysis of renal cell carcinoma
J Clin Oncol (Meeting Abstracts) 2006 24: 14548. [Abstract]  

T. A. Mays, J. Sarantopoulos, A. Tolcher, I. Lowy, G. Preston, E. Levy, M. D. Oslund, E. Manchen, A. Kelly, and W. M. Stadler

MDX-070, a human anti-plasma antibody, administered as either a single dose or as multiple doses to patients with hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14549. [Abstract]  

T. E. Hutson, S. Vukelja, S. Nicol, K. E. Hood, A. Delgado, D. Ilegbodu, and W. R. Berry

Phase I study of gemcitabine and cisplatin followed by pemetrexed and gemcitabine in patients with metastatic transitional cell carcinoma of the urothelium: Preliminary results
J Clin Oncol (Meeting Abstracts) 2006 24: 14550. [Abstract]  

T. R. Blom, R. A. Somer, W. Shih, M. Sarno, D. McNally, M. Todd, S. Yao, G. Lu-Yao, R. Dipaola, and M. N. Stein

Variation in local treatment of prostate cancer by hospital within New Jersey
J Clin Oncol (Meeting Abstracts) 2006 24: 14551. [Abstract]  

N. Sharifi, E. Hurt, and W. L. Farrar

TGFBR3 is lost in prostate cancer, contributing to malignant transformation
J Clin Oncol (Meeting Abstracts) 2006 24: 14552. [Abstract]  

D. E. Linstadt, M. Logsdon, D. Stickney, D. Chabra, M. Russo, and S. Workman

Permanent ¹²⁵I prostate brachytherapy outcome in patients younger than 60
J Clin Oncol (Meeting Abstracts) 2006 24: 14553. [Abstract]  

R. Molife, S. Patterson, C. Riggs, C. Higano, W. M. Stadler, D. Dearnaley, C. Parker, W. McCulloch, A. Shalaurov, and J. S. De-Bono

Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14554. [Abstract]  

T. McCann, P. M. Pierorazio, R. Mitchell, M. Desai, C. A. Olsson, M. C. Benson, and J. McKiernan

Pre-biopsy PSA and biopsy gleason sum; evaluating the independence of two independent variables
J Clin Oncol (Meeting Abstracts) 2006 24: 14555. [Abstract]  

T. Wiegel, G. Lohm, S. Hoecht, D. Bottke, K. Neumann, and W. Hinkelbein

Salvage radiotherapy (SR) in patients (pts) with prostate cancer (PC) and rising prostate specific antigen (PSA) after radical prostatectomy (RP): Results from a single-center study
J Clin Oncol (Meeting Abstracts) 2006 24: 14556. [Abstract]  

J. Stephenson, R. J. Amato, S. Hotte, J. Nemunaitis, B. Berman, K. Bélanger, T. A. Patterson, A. R. Macleod, G. K. Reid, and R. E. Martell

A dose and schedule optimizing evaluation of MG98 given as either a 2 hour IV infusion twice weekly or as a 7 day continuous infusion in combination with interferon alpha (INF) in nephrectomized patients (pts) with advanced renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2006 24: 14557. [Abstract]  

A. Bamias, E. Kastritis, G. Bozas, V. Koutsoukou, N. Antoniou, H. Katsifotis, K. Konstantinidis, A. Skolarikos, C. Deliveliotis, and M. A. Dimopoulos

Cisplatin versus carboplatin-based chemotherapy in inoperable or recurrent urothelial carcinoma: A retrospective analysis
J Clin Oncol (Meeting Abstracts) 2006 24: 14558. [Abstract]  

S. Sewak, S. Kosmider, V. Ganju, A. Woollett, B. Le, E. Yeow, M. Henry, and R. Bell

A phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer (HRPC): Double tubulin targeting
J Clin Oncol (Meeting Abstracts) 2006 24: 14559. [Abstract]  

F. Merlin, M. Riolfi, T. Sava, F. Consoli, C. Griso, P. Manno, A. B. Porcaro, C. Ghimenton, L. Comunale, and G. Cetto

Upper urinary tract cancer: Prognostic factors for bladder tumours development and systemic relapse
J Clin Oncol (Meeting Abstracts) 2006 24: 14560. [Abstract]  

N. T. Karanikolas, F. P. Secin, J. Stasi, B. S. Carver, Z. Dotan, and J. Sheinfeld

Non-seminomatous retroperitoneal histology in patients with a pure testicular seminoma and an elevated serum alpha feto-protein
J Clin Oncol (Meeting Abstracts) 2006 24: 14561. [Abstract]  

G. Pomara, M. Simone, L. Fontana, S. Giusti, C. Bartolozzi, and F. Francesca

DHAIS (Diagnosis-Helping-Accuracy-Imaging-Study) study: Combined endorectal MR and MR spectroscopic imaging in the diagnosis of prostate cancer
J Clin Oncol (Meeting Abstracts) 2006 24: 14562. [Abstract]